ES2891825T3 - Método para producir un derivado de difenilmetano - Google Patents

Método para producir un derivado de difenilmetano Download PDF

Info

Publication number
ES2891825T3
ES2891825T3 ES17813615T ES17813615T ES2891825T3 ES 2891825 T3 ES2891825 T3 ES 2891825T3 ES 17813615 T ES17813615 T ES 17813615T ES 17813615 T ES17813615 T ES 17813615T ES 2891825 T3 ES2891825 T3 ES 2891825T3
Authority
ES
Spain
Prior art keywords
compound
formula
following formula
alkyl
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17813615T
Other languages
English (en)
Spanish (es)
Inventor
Hee-Kyoon Yoon
Se-Hwan Park
Ji-Sung Yoon
Soongyu Choi
Hee Jeong Seo
Eun-Jung Park
Younggyu Kong
Kwang-Seop Song
Min Ju Kim
So Ok Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Pharmaceutical Co Ltd
GC Biopharma Corp
Original Assignee
Green Cross Corp Korea
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2891825(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Green Cross Corp Korea, Daewoong Pharmaceutical Co Ltd filed Critical Green Cross Corp Korea
Application granted granted Critical
Publication of ES2891825T3 publication Critical patent/ES2891825T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/005Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17813615T 2016-06-17 2017-06-15 Método para producir un derivado de difenilmetano Active ES2891825T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160075910 2016-06-17
PCT/KR2017/006271 WO2017217792A1 (ko) 2016-06-17 2017-06-15 다이페닐메탄 유도체의 제조방법

Publications (1)

Publication Number Publication Date
ES2891825T3 true ES2891825T3 (es) 2022-01-31

Family

ID=60664449

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17813615T Active ES2891825T3 (es) 2016-06-17 2017-06-15 Método para producir un derivado de difenilmetano
ES20152959T Active ES2898336T3 (es) 2016-06-17 2017-06-15 Derivado de difenilmetano en forma cristalina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES20152959T Active ES2898336T3 (es) 2016-06-17 2017-06-15 Derivado de difenilmetano en forma cristalina

Country Status (29)

Country Link
US (2) US10640496B2 (enExample)
EP (2) EP3663292B1 (enExample)
JP (4) JP6763978B2 (enExample)
KR (2) KR102233229B1 (enExample)
CN (2) CN113651803B (enExample)
AU (1) AU2017285813B2 (enExample)
CA (2) CA3026756C (enExample)
CL (1) CL2018003645A1 (enExample)
CO (1) CO2018014018A2 (enExample)
DK (2) DK3663292T3 (enExample)
DO (1) DOP2018000287A (enExample)
EC (1) ECSP19000185A (enExample)
ES (2) ES2891825T3 (enExample)
HR (1) HRP20211670T8 (enExample)
HU (1) HUE056428T2 (enExample)
MA (2) MA50774B1 (enExample)
MX (2) MX392177B (enExample)
MY (1) MY203941A (enExample)
NZ (1) NZ749398A (enExample)
PE (2) PE20190467A1 (enExample)
PH (1) PH12018550206A1 (enExample)
PL (2) PL3473621T3 (enExample)
PT (2) PT3473621T (enExample)
RS (1) RS62550B1 (enExample)
SA (2) SA521422474B1 (enExample)
SG (2) SG11201811154QA (enExample)
SI (1) SI3663292T1 (enExample)
TN (1) TN2018000437A1 (enExample)
WO (1) WO2017217792A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011054773A1 (de) 2011-10-25 2013-04-25 Vb Autobatterie Gmbh & Co. Kgaa Anschlusspol für einen Akkumulator, Akkumulatorgehäuse und Maschine zur Herstellung eines Anschlusspols
PE20211206A1 (es) * 2018-08-13 2021-07-05 Dae Woong Pharma Preparacion de intermedio util para la sintesis de inhibidor de sglt
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
WO2021172955A1 (ko) * 2020-02-27 2021-09-02 주식회사 대웅제약 Sglt 저해제의 합성에 유용한 중간체 및 이를 이용한 sglt 저해제의 제조 방법
US12448360B2 (en) * 2020-09-10 2025-10-21 Daewoong Pharmaceutical Co., Ltd. Synthesis method for preparing SGLT inhibitor intermediate
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
CN113200860B (zh) * 2021-04-29 2024-07-30 爱斯特(成都)生物制药股份有限公司 一种sglt2抑制剂中间体的制备方法
KR20230046784A (ko) * 2021-09-30 2023-04-06 주식회사 대웅제약 이나보글리플로진을 포함하는 약학 조성물
CN113801010A (zh) * 2021-11-18 2021-12-17 山东诚创蓝海医药科技有限公司 一种5-溴-2-氯苯甲酸的制备方法
CN113912487B (zh) * 2021-11-23 2024-05-28 山东研峰新材料科技有限公司 一种2,5-双卤代苯甲酸的合成方法
KR20230110001A (ko) * 2022-01-14 2023-07-21 주식회사 대웅제약 Ssglt 저해제의 합성에 유용한 중간체의 제조 방법
KR20240044190A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법
KR20240044194A (ko) 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정
CN119968202A (zh) 2022-09-29 2025-05-09 株式会社大熊制药 用于预防或治疗心血管衰老疾病的包含依那格列净的药物组合物
KR20240047952A (ko) 2022-10-05 2024-04-12 주식회사 대웅제약 이나보글리플로진을 포함하는 신장애 및/또는 당뇨병 예방 또는 치료용 약학 조성물
EP4631498A1 (en) 2022-12-21 2025-10-15 Daewoong Therapeutics Inc. Eye drop-type pharmaceutical composition containing envogliflozin
KR20240107660A (ko) 2022-12-30 2024-07-09 주식회사 대웅제약 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물
KR102853437B1 (ko) * 2024-11-13 2025-09-04 대웅바이오(주) 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837948B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) 분배 투입법을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법
KR102837941B1 (ko) * 2024-11-13 2025-07-25 대웅바이오(주) Inline quenching 공정을 도입한 연속반응 공정을 이용한 이나보글리플로진 합성방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966907A (en) * 1988-08-12 1990-10-30 Merck & Co., Inc. 6-substituted 5-hydroxy-2,3-dihydrobenzofurans as inhibitors of leukotriene biosynthesis
EP2514756B1 (en) * 2003-08-01 2014-12-17 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
WO2009014970A1 (en) 2007-07-26 2009-01-29 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
WO2010012789A1 (en) 2008-07-30 2010-02-04 Ferrer Internacional S. A. 1,6-dihydro-2h-3-oxa-6-aza-as-indacene compounds
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
KR101576589B1 (ko) * 2011-06-01 2015-12-10 주식회사 녹십자 Sglt2 억제제로서의 신규한 다이페닐메탄 유도체
US9340521B2 (en) 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PE20190467A1 (es) 2019-04-04
KR20170142904A (ko) 2017-12-28
CN113651803A (zh) 2021-11-16
MX2021008988A (es) 2022-05-05
US20190382390A1 (en) 2019-12-19
SG10201911782RA (en) 2020-02-27
EP3663292B1 (en) 2021-09-01
US10889574B2 (en) 2021-01-12
PT3473621T (pt) 2021-10-04
ES2898336T3 (es) 2022-03-07
SA518400666B1 (ar) 2021-11-30
JP2021152054A (ja) 2021-09-30
JP6763978B2 (ja) 2020-09-30
CN113651803B (zh) 2022-10-28
EP3473621B1 (en) 2021-08-04
PT3663292T (pt) 2021-11-08
HUE056428T2 (hu) 2022-02-28
DK3473621T3 (da) 2021-09-06
US20190169174A1 (en) 2019-06-06
CO2018014018A2 (es) 2019-03-08
RU2021129636A (ru) 2021-11-22
AU2017285813A1 (en) 2019-01-17
HRP20211670T8 (hr) 2022-03-18
EP3473621A4 (en) 2020-03-11
NZ749398A (en) 2020-01-31
KR20210036892A (ko) 2021-04-05
WO2017217792A1 (ko) 2017-12-21
PL3473621T3 (pl) 2022-01-10
PH12018550206A1 (en) 2019-09-30
MX2018015647A (es) 2019-04-11
MA44545B2 (fr) 2020-11-30
JP7669206B2 (ja) 2025-04-28
EP3663292A1 (en) 2020-06-10
JP7773506B2 (ja) 2025-11-19
MY203941A (en) 2024-07-25
PE20240590A1 (es) 2024-03-21
CN109311861B (zh) 2021-08-24
JP2020117528A (ja) 2020-08-06
JP2019521985A (ja) 2019-08-08
CA3081033C (en) 2022-04-12
SG11201811154QA (en) 2019-01-30
BR112018076243A2 (pt) 2019-03-26
MA44545B1 (fr) 2020-05-29
TN2018000437A1 (en) 2020-06-15
MA44545A1 (fr) 2019-10-31
AU2017285813B2 (en) 2020-02-06
ECSP19000185A (es) 2019-01-31
CA3026756C (en) 2021-03-02
KR102379584B1 (ko) 2022-03-29
DK3663292T3 (da) 2021-10-25
CN109311861A (zh) 2019-02-05
DOP2018000287A (es) 2019-03-31
EP3473621A1 (en) 2019-04-24
MX392177B (es) 2025-03-19
RU2019101056A (ru) 2020-07-17
CA3026756A1 (en) 2017-12-21
JP7352509B2 (ja) 2023-09-28
SA521422474B1 (ar) 2023-11-02
HRP20211670T1 (hr) 2022-02-18
CL2018003645A1 (es) 2019-03-22
RS62550B1 (sr) 2021-12-31
PL3663292T3 (pl) 2022-01-17
RU2019101056A3 (enExample) 2020-07-17
MA50774A1 (fr) 2021-03-31
SI3663292T1 (sl) 2022-01-31
MX385640B (es) 2025-03-18
MA50774B1 (fr) 2022-02-28
KR102233229B1 (ko) 2021-03-29
CA3081033A1 (en) 2017-12-21
JP2023145481A (ja) 2023-10-11
US10640496B2 (en) 2020-05-05

Similar Documents

Publication Publication Date Title
ES2891825T3 (es) Método para producir un derivado de difenilmetano
EP3133071B1 (en) C-aryl indican derivative, and pharmaceutical composition thereof, preparation method therefor and uses thereof
CN107108539A (zh) 钠‑葡萄糖协同转运蛋白2(sglt‑2)抑制剂
CN115087649A (zh) 用于合成sglt抑制剂的中间体和使用该中间体制备sglt抑制剂的方法
KR102307475B1 (ko) Sglt 저해제의 합성에 유용한 중간체의 제조
KR101770302B1 (ko) 다이페닐메탄 유도체의 제조방법
RU2814846C1 (ru) Способ получения производного дифенилметана
RU2774998C2 (ru) Способ получения производного дифенилметана
RU2797392C2 (ru) Способ получения производного дифенилметана
BR112018076243B1 (pt) Método para produzir um composto derivado de difenil metano e forma cristalina do composto produzido pelo dito método
HK40057423B (en) Method for producing diphenylmethane derivative
HK40057423A (en) Method for producing diphenylmethane derivative
HK40002293A (en) Method for producing diphenylmethane derivative
HK40002293B (zh) 用於制备二苯基甲烷衍生物的方法
ES2638915T3 (es) Procedimiento de preparación de compuestos usados como inhibidores de SGLT-22